Scarica l'app Stockscreener
38.02
2.34%
-0.91
Dopo l'orario di chiusura:
38.02
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Why is Xenon Pharmaceuticals stock rallying today? - Investing.com India
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month - TradingView
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - marketscreener.com
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
Xenon Pharmaceuticals President & CEO Purchased Shares Worth Over $1.1M - TradingView
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Ian Mortimer Receives the 2026 Bloom Burton Award - Nasdaq
Defence Therapeutics appoints Sherry Aulin to B... - Pluang
Jefferies cuts Xenon Pharmaceuticals stock price target on trial pause By Investing.com - Investing.com Canada
Xenon Pharmaceuticals Inc. (XENE) Latest Stock News & HeadlinesYahoo Finance - ca.finance.yahoo.com
(XENE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance UK
XENE Investor Alert: Levi & Korsinsky Investigates Xenon Pharmaceuticals Inc. (XENE) For Potential Securities Fraud - ACCESS Newswire
Levi & Korsinsky Announces Investigation of Securities Claims Against Xenon Pharmaceuticals Inc. (XENE) - ACCESS Newswire
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Insider Monkey
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - Block Island Times
Xenon Pharmaceuticals stock falls 30.69 percent as trial pause hits - AD HOC NEWS
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures - NeurologyLive
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Craters 30%: Reading the Charts After the Depression Trial Pause - MEXC
Company News for Sep 21, 2026 - Yahoo Finance
Xenon shares slide more than 30% as company pauses psychiatry trial enrollment - thepharmaletter.com
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - TIKR.com
Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why - webull.com
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Envista Holdings (NVST) - The Globe and Mail
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
XENE Stock Drops 30% on Phase 3 Trial Halt; Price-to-Sales Ratio Signals Market Skepticism - GuruFocus
Xenon Halts Enrollment in Depression Trials After Psychosis Reports - finance.biggo.com
Xenon downgraded at Deutsche Bank on trial pause (XENE:NASDAQ) - Seeking Alpha
Xenon stock plunges as B.C. drug developer pauses enrolment in depression study - The Globe and Mail
Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade) (NASDAQ:XENE) - Seeking Alpha
Dow Falls Over 200 Points; Xenon Pharmaceuticals Shares Plunge - Benzinga
Xenon: FOS read-across in MDD, BD hitches with Kv7? - BioWorld News
Xenon Pharmaceuticals Faces Setback Amid Clinical Study Pause - GuruFocus
XENE Maintains Outperform Rating -- Price Target Lowered to $70 - GuruFocus
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets Says - marketscreener.com
Xenon Stock Reaction Is Overblown: Analyst - TradingView
Xenon pauses depression trial enrollment after side effects - grafa.com
XENE Maintained by Wedbush -- Price Target Lowered to $55 - GuruFocus
Xenon Pharmaceuticals sinks as psychiatry trial pause overshadows epilepsy NDA filing - quiverquant.com
Goldman Sachs Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $75 - moomoo.com
Market movers: Netflix, Xenon Pharmaceuticals, Ocean Power Technologies... - Proactive financial news
RBC Capital maintains Outperform rating on Xenon Pharmaceuticals, $70 price target - TradingView
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):